Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

RGD conjugated cell uptake off to on responsive NIR-AZA fluorophores: applications toward intraoperative fluorescence guided surgery.

Wu D, Daly HC, Grossi M, Conroy E, Li B, Gallagher WM, Elmes R, O'Shea DF.

Chem Sci. 2019 Jun 21;10(29):6944-6956. doi: 10.1039/c9sc02197c. eCollection 2019 Aug 7.

2.

BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.

Walsh L, Haley KE, Moran B, Mooney B, Tarrant F, Madden SF, Di Grande A, Fan Y, Das S, Rueda OM, Dowling CM, Varešlija D, Chin SF, Linn S, Young LS, Jirström K, Crown JP, Bernards R, Caldas C, Gallagher WM, O'Connor DP, Ní Chonghaile T.

Clin Cancer Res. 2019 Aug 13. doi: 10.1158/1078-0432.CCR-19-0713. [Epub ahead of print]

PMID:
31409615
3.

Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents.

Miller IS, Shiels LP, Conroy E, Connor K, Dicker P, Gallagher WM, Donovan NO, Kerbel RS, Crown J, Byrne AT.

Sci Rep. 2019 Jun 24;9(1):9204. doi: 10.1038/s41598-019-45444-0.

4.

1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours.

Butler CT, Kennedy SA, Buckley A, Doyle R, Conroy E, Gallagher WM, O'Sullivan J, Kennedy BN.

Oncotarget. 2019 Jun 4;10(38):3725-3744. doi: 10.18632/oncotarget.26966. eCollection 2019 Jun 4.

5.

Correction: BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.

Shields S, Conroy E, O'Grady T, McGoldrick A, Connor K, Ward MP, Useckaite Z, Dempsey E, Reilly R, Fan Y, Chubb A, Matallanas DG, Kay EW, O'Connor D, McCann A, Gallagher WM, Coppinger JA.

Oncotarget. 2019 May 3;10(33):3144. doi: 10.18632/oncotarget.26920. eCollection 2019 May 3.

6.

A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic.

Salvucci M, Rahman A, Resler AJ, Udupi GM, McNamara DA, Kay EW, Laurent-Puig P, Longley DB, Johnston PG, Lawler M, Wilson R, Salto-Tellez M, Van Schaeybroeck S, Rafferty M, Gallagher WM, Rehm M, Prehn JHM.

JCO Clin Cancer Inform. 2019 Apr;3:1-17. doi: 10.1200/CCI.18.00056.

7.

PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer.

Cox OT, Edmunds SJ, Simon-Keller K, Li B, Moran B, Buckley NE, Bustamante-Garrido M, Healy N, O'Flanagan CH, Gallagher WM, Kennedy RD, Bernards R, Caldas C, Chin SF, Marx A, O'Connor R.

Cancer Res. 2019 May 15;79(10):2619-2633. doi: 10.1158/0008-5472.CAN-18-2787. Epub 2019 Mar 18.

PMID:
30885980
8.

epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer.

O'Reilly E, Tuzova AV, Walsh AL, Russell NM, O'Brien O, Kelly S, Dhomhnallain ON, DeBarra L, Dale CM, Brugman R, Clarke G, Schmidt O, O'Meachair S, Patil D, Pellegrini KL, Fleshner N, Garcia J, Zhao F, Finn S, Mills R, Hanna MY, Hurst R, McEvoy E, Gallagher WM, Manecksha RP, Cooper CS, Brewer DS, Bapat B, Sanda MG, Clark J, Perry AS.

JCO Precis Oncol. 2019;2019. doi: 10.1200/PO.18.00134. Epub 2019 Jan 14.

9.

Targeted DNA Methylation Profiling of Human Cardiac Tissue Reveals Novel Epigenetic Traits and Gene Deregulation Across Different Heart Failure Patient Subtypes.

Glezeva N, Moran B, Collier P, Moravec CS, Phelan D, Donnellan E, Russell-Hallinan A, O'Connor DP, Gallagher WM, Gallagher J, McDonald K, Ledwidge M, Baugh J, Das S, Watson CJ.

Circ Heart Fail. 2019 Mar;12(3):e005765. doi: 10.1161/CIRCHEARTFAILURE.118.005765.

PMID:
30798618
10.

Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre-Clinical Detection of Off-Target Toxicities Associated with Sunitinib Malate.

O'Farrell AC, Miller IS, Evans R, Alamanou M, Cary M, Mallya Udupi G, Lafferty A, Monsefi N, Cremona M, Prehn JHM, Verheul HM, Gallagher WM, Gehrmann M, Byrne AT.

Proteomics Clin Appl. 2019 Jul;13(4):e1800159. doi: 10.1002/prca.201800159. Epub 2019 Mar 19.

PMID:
30768761
11.

PEGylated BF2-Azadipyrromethene (NIR-AZA) fluorophores, for intraoperative imaging.

Wu D, Daly HC, Conroy E, Li B, Gallagher WM, Cahill RA, O'Shea DF.

Eur J Med Chem. 2019 Jan 1;161:343-353. doi: 10.1016/j.ejmech.2018.10.046. Epub 2018 Oct 19.

PMID:
30368132
12.

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J.

BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1.

13.

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.

Smeets D, Miller IS, O'Connor DP, Das S, Moran B, Boeckx B, Gaiser T, Betge J, Barat A, Klinger R, van Grieken NCT, Cremolini C, Prenen H, Mazzone M, Depreeuw J, Bacon O, Fender B, Brady J, Hennessy BT, McNamara DA, Kay E, Verheul HM, Maarten N, Gallagher WM, Murphy V, Prehn JHM, Koopman M, Punt CJA, Loupakis F, Ebert MPA, Ylstra B, Lambrechts D, Byrne AT.

Nat Commun. 2018 Oct 5;9(1):4112. doi: 10.1038/s41467-018-06567-6.

14.

Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers.

Lindner AU, Lucantoni F, Varešlija D, Resler A, Murphy BM, Gallagher WM, Hill ADK, Young LS, Prehn JHM.

J Mol Med (Berl). 2018 Oct;96(10):1025-1037. doi: 10.1007/s00109-018-1675-0. Epub 2018 Aug 1.

PMID:
30069746
15.

Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.

van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy V, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA, Kay EW, Hennessey BT, Verheul HMW, Gallagher WM, O'Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B.

J Clin Oncol. 2018 Jul 10;36(20):2052-2060. doi: 10.1200/JCO.2017.77.1782. Epub 2018 May 24.

PMID:
29792754
16.

BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.

Shields S, Conroy E, O'Grady T, McGoldrick A, Connor K, Ward MP, Useckaite Z, Dempsey E, Reilly R, Fan Y, Chubb A, Matallanas DG, Kay EW, O'Connor D, McCann A, Gallagher WM, Coppinger JA.

Oncotarget. 2018 Feb 28;9(21):15673-15690. doi: 10.18632/oncotarget.24590. eCollection 2018 Mar 20. Erratum in: Oncotarget. 2019 May 3;10(33):3144.

17.

Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.

O'Brien KP, Khan S, Gilligan KE, Zafar H, Lalor P, Glynn C, O'Flatharta C, Ingoldsby H, Dockery P, De Bhulbh A, Schweber JR, St John K, Leahy M, Murphy JM, Gallagher WM, O'Brien T, Kerin MJ, Dwyer RM.

Oncogene. 2018 Apr;37(16):2137-2149. doi: 10.1038/s41388-017-0116-9. Epub 2018 Jan 25.

PMID:
29367765
18.

Epigenetics of malignant melanoma.

Moran B, Silva R, Perry AS, Gallagher WM.

Semin Cancer Biol. 2018 Aug;51:80-88. doi: 10.1016/j.semcancer.2017.10.006. Epub 2017 Oct 23. Review.

PMID:
29074395
19.

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.

Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O'Donovan N, O'Connor D, Gallagher WM, Crown J, Fersht AR, Duffy MJ.

Cancer Lett. 2018 Feb 1;414:99-106. doi: 10.1016/j.canlet.2017.09.053. Epub 2017 Oct 22.

PMID:
29069577
20.

Absolute Quantification of Toxicological Biomarkers via Mass Spectrometry.

Lau TYK, Collins BC, Stone P, Tang N, Gallagher WM, Pennington SR.

Methods Mol Biol. 2017;1641:337-348. doi: 10.1007/978-1-4939-7172-5_19.

PMID:
28748474
21.

Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.

Moran B, Das S, Smeets D, Peutman G, Klinger R, Fender B, Connor K, Ebert M, Gaiser T, Prehn JH, Bacon O, Kay E, Hennessy B, Murphy V, Ylstra B, Lambrechts D, Byrne AT, Gallagher WM, O'Connor DP.

Oncotarget. 2017 Jul 18;8(29):48126-48137. doi: 10.18632/oncotarget.18296.

22.

Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma.

Wouters J, Vizoso M, Martinez-Cardus A, Carmona FJ, Govaere O, Laguna T, Joseph J, Dynoodt P, Aura C, Foth M, Cloots R, van den Hurk K, Balint B, Murphy IG, McDermott EW, Sheahan K, Jirström K, Nodin B, Mallya-Udupi G, van den Oord JJ, Gallagher WM, Esteller M.

BMC Med. 2017 Jun 5;15(1):101. doi: 10.1186/s12916-017-0851-3.

23.

Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.

Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R.

Oncotarget. 2017 Jun 27;8(26):42949-42961. doi: 10.18632/oncotarget.17306.

24.

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

Li B, Ni Chonghaile T, Fan Y, Madden SF, Klinger R, O'Connor AE, Walsh L, O'Hurley G, Mallya Udupi G, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn S, Jirstrom K, Caldas C, O'Connor DP, Gallagher WM.

Cancer Res. 2017 Jul 15;77(14):3834-3845. doi: 10.1158/0008-5472.CAN-16-2546. Epub 2017 Apr 28.

25.

Master Transcriptional Regulators in Cancer: Discovery via Reverse Engineering Approaches and Subsequent Validation.

Moran B, Rahman A, Palonen K, Lanigan FT, Gallagher WM.

Cancer Res. 2017 May 1;77(9):2186-2190. doi: 10.1158/0008-5472.CAN-16-1813. Epub 2017 Apr 20. Review.

26.

The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways.

Dwane L, Gallagher WM, Ní Chonghaile T, O'Connor DP.

J Biol Chem. 2017 Mar 3;292(9):3543-3551. doi: 10.1074/jbc.R116.755694. Epub 2017 Feb 1. Review.

27.

A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.

O'Farrell AC, Evans R, Silvola JM, Miller IS, Conroy E, Hector S, Cary M, Murray DW, Jarzabek MA, Maratha A, Alamanou M, Udupi GM, Shiels L, Pallaud C, Saraste A, Liljenbäck H, Jauhiainen M, Oikonen V, Ducret A, Cutler P, McAuliffe FM, Rousseau JA, Lecomte R, Gascon S, Arany Z, Ky B, Force T, Knuuti J, Gallagher WM, Roivainen A, Byrne AT.

PLoS One. 2017 Jan 27;12(1):e0169964. doi: 10.1371/journal.pone.0169964. eCollection 2017.

28.

Circulating MicroRNAs in Cancer.

O'Brien KP, Ramphul E, Howard L, Gallagher WM, Malone C, Kerin MJ, Dwyer RM.

Methods Mol Biol. 2017;1509:123-139.

PMID:
27826923
29.

Assessment of Significance of Novel Proteins in Breast Cancer Using Tissue Microarray Technology.

Mulrane L, Gallagher WM, O'Connor DP.

Methods Mol Biol. 2017;1501:311-325.

PMID:
27796961
30.

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.

Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ.

Oncotarget. 2016 Nov 15;7(46):75518-75525. doi: 10.18632/oncotarget.12782.

31.

Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.

Murphy AG, Casey R, Maguire A, Tosetto M, Butler CT, Conroy E, Reynolds AL, Sheahan K, O'Donoghue D, Gallagher WM, Fennelly D, Kennedy BN, O'Sullivan J.

Sci Rep. 2016 Oct 14;6:34523. doi: 10.1038/srep34523.

32.

Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer.

Burke L, Butler CT, Murphy A, Moran B, Gallagher WM, O'Sullivan J, Kennedy BN.

Front Cell Dev Biol. 2016 Sep 21;4:103. eCollection 2016. Review.

33.

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J, Duffy MJ.

Int J Cancer. 2017 Jan 1;140(1):234-246. doi: 10.1002/ijc.30425. Epub 2016 Sep 24.

34.

De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.

Smith A, Murphy L, Sharp L, O'Connor D, Gallagher WM, Bennett K, Barron TI.

Br J Cancer. 2016 Aug 23;115(5):592-8. doi: 10.1038/bjc.2016.232. Epub 2016 Aug 2.

35.

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, Young L, Kay EW, O'Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT.

J Natl Cancer Inst. 2016 Jul 4;108(8). pii: djw111. doi: 10.1093/jnci/djw111. Print 2016 Aug. No abstract available.

36.

Functionalization of emissive conjugated polymer nanoparticles by coprecipitation: consequences for particle photophysics and colloidal properties.

Singh A, Bezuidenhout M, Walsh N, Beirne J, Felletti R, Wang S, Fitzgerald KT, Gallagher WM, Kiely P, Redmond G.

Nanotechnology. 2016 Jul 29;27(30):305603. doi: 10.1088/0957-4484/27/30/305603. Epub 2016 Jun 16.

PMID:
27306338
37.

Lysosome triggered near-infrared fluorescence imaging of cellular trafficking processes in real time.

Grossi M, Morgunova M, Cheung S, Scholz D, Conroy E, Terrile M, Panarella A, Simpson JC, Gallagher WM, O'Shea DF.

Nat Commun. 2016 Mar 1;7:10855. doi: 10.1038/ncomms10855.

38.

Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.

Walsh L, Gallagher WM, O'Connor DP, Ní Chonghaile T.

Expert Rev Mol Diagn. 2016;16(5):541-51. doi: 10.1586/14737159.2016.1156534. Epub 2016 Mar 16. Review.

PMID:
26895288
39.

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR, Gaber A, O'Hurley G, Lehn S, Muris JJ, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O'Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirström K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R.

Sci Rep. 2016 Jan 5;6:18517. doi: 10.1038/srep18517.

40.

Prognostic and predictive biomarkers in melanoma: an update.

Foth M, Wouters J, de Chaumont C, Dynoodt P, Gallagher WM.

Expert Rev Mol Diagn. 2016;16(2):223-37. doi: 10.1586/14737159.2016.1126511. Epub 2015 Dec 22. Review.

PMID:
26620320
41.

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.

O'Callaghan DS, Rexhepaj E, Gately K, Coate L, Delaney D, O'Donnell DM, Kay E, O'Connell F, Gallagher WM, O'Byrne KJ.

Eur Respir J. 2015 Dec;46(6):1762-72. doi: 10.1183/13993003.00176-2014. Epub 2015 Nov 5.

42.

The Role of Exosomes in Breast Cancer.

Lowry MC, Gallagher WM, O'Driscoll L.

Clin Chem. 2015 Dec;61(12):1457-65. doi: 10.1373/clinchem.2015.240028. Epub 2015 Oct 14. Review.

43.

miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.

O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O'Driscoll L.

Oncotarget. 2015 Oct 20;6(32):32774-89. doi: 10.18632/oncotarget.5192.

44.

Relationship between serum response factor and androgen receptor in prostate cancer.

Prencipe M, O'Neill A, O'Hurley G, Nguyen LK, Fabre A, Bjartell A, Gallagher WM, Morrissey C, Kay EW, Watson RW.

Prostate. 2015 Nov;75(15):1704-17. doi: 10.1002/pros.23051. Epub 2015 Aug 7.

45.

Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer.

O'Hurley G, Busch C, Fagerberg L, Hallström BM, Stadler C, Tolf A, Lundberg E, Schwenk JM, Jirström K, Bjartell A, Gallagher WM, Uhlén M, Pontén F.

PLoS One. 2015 Aug 3;10(8):e0133449. doi: 10.1371/journal.pone.0133449. eCollection 2015.

46.

Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients.

Lanigan F, Brien GL, Fan Y, Madden SF, Jerman E, Maratha A, Aloraifi F, Hokamp K, Dunne EJ, Lohan AJ, Flanagan L, Garbe JC, Stampfer MR, Fridberg M, Jirstrom K, Quinn CM, Loftus B, Gallagher WM, Geraghty J, Bracken AP.

FEBS J. 2015 Sep;282(18):3455-73. doi: 10.1111/febs.13354. Epub 2015 Jul 14.

47.

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M.

Nat Med. 2015 Jul;21(7):741-50. doi: 10.1038/nm.3863. Epub 2015 Jun 1.

48.

FKBPL: a marker of good prognosis in breast cancer.

Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T.

Oncotarget. 2015 May 20;6(14):12209-23.

49.

The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides.

Szwej E, Devocelle M, Kenny S, Guzik M, O'Connor S, Nikodinovic-Runic J, Radivojevic J, Maslak V, Byrne AT, Gallagher WM, Zulian QR, Zinn M, O'Connor KE.

J Biotechnol. 2015 Jun 20;204:7-12. doi: 10.1016/j.jbiotec.2015.02.036. Epub 2015 Mar 24.

PMID:
25820126
50.

Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies.

Mischak H, Critselis E, Hanash S, Gallagher WM, Vlahou A, Ioannidis JP.

Am J Epidemiol. 2015 May 1;181(9):635-47. doi: 10.1093/aje/kwu462. Epub 2015 Mar 19. Review.

PMID:
25792606

Supplemental Content

Loading ...
Support Center